The deferasirox-AmBisome therapy for mucormycosis (Defeat Mucor) study: A randomized, double-blinded, placebo-controlled trial

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 715-722

  Spellberg, Brad ^a,b   Ibrahim, Ashraf S ^a,b   Chin Hong, Peter V ^c   Kontoyiannis, Dimitrios P ^d   Morris, Michele I ^e   Perfect, John R ^f   Fredricks, David ^g   Brass, Eric P ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e JACKSON MEMORIAL HOSPITAL   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal; Combination therapy; Fungal infections; Mould infections

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CREATININE; DEFERASIROX; ECHINOCANDIN; PLACEBO; POSACONAZOLE;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BLURRED VISION; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DEBRIDEMENT; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXOPHTHALMOS; FEMALE; FEVER; HEART ARRHYTHMIA; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOMAGNESEMIA; HYPOXIA; INSOMNIA; KIDNEY FAILURE; LIVER FAILURE; LUNG HEMORRHAGE; LUNG INSUFFICIENCY; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC ACIDOSIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MUCORMYCOSIS; MULTICENTER STUDY; MYOCLONUS; NEUTROPENIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; VOMITING;

ADULT; AGED; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BENZOIC ACIDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; MICE; MIDDLE AGED; MUCORMYCOSIS; PLACEBOS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84856967582     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr375     Document Type: Article

References (32)

1. Ibrahim AS, Gebermariam T, Fu Y et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117: 2649-57.
2. Liu M, Spellberg B, Phan QT et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010; 120: 1914-24.
3. Abe F, Shibuya H, Tateyama M et al. Mucormycosis in diabetic ketoacidosis. Role of unbound iron binding capacity of transferrin. Acta Pathol Jpn 1986; 36: 1507-12.
4. Artis WM, Fountain JA, Delcher HK et al. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982; 31: 1109-14.
5. Eiser AR, Slifkin RF, Neff MS. Intestinal mucormycosis in hemodialysis patients following deferoxamine. Am J Kidney Dis 1987; 10: 71-3.
6. Windus DW, Stokes TJ, Julian BA et al. Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine. Ann Intern Med 1987; 107: 678-80.
7. Daly AL, Velazquez LA, Bradley SF et al. Mucormycosis: association with deferoxamine therapy. Am J Med 1989; 87: 468-71.
8. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991; 18: 660-7.
9. Boelaert JR, de Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993; 91: 1979-86.
10. de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 1994; 47: 1843-50.
11. Boelaert JR, de Locht M, Schneider YJ. The effect of deferoxamine on different zygomycetes. J Infect Dis 1994; 169: 231-2.
12. Boelaert JR, Van Cutsem J, de Locht M et al. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994; 45: 667-71.
13. Van Cutsem J, Boelaert JR. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 1989; 36: 1061-8.
14. Abe F, Inaba H, Katoh T et al. Effects of iron and desferrioxamine on Rhizopus infection. Mycopathologia 1990; 110: 87-91.
15. Ibrahim AS, Edwards JE Jr, Fu Y et al. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006; 58: 1070-3.
16. Chamilos G, Lewis RE, Hu J et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci USA 2008; 105: 9367-72.
17. Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 2005; 18: 289-98.
18. Reed C, Ibrahim A, Edwards JE Jr et al. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006; 50: 3968-9.
19. Spellberg B, Andes D, Perez M et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009; 53: 3122-5.
20. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
21. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-9.
22. Spellberg B, Walsh TJ, Kontoyiannis DP et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743-51.
23. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
24. Shoham S, Magill SS, Merz WG et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol 2010; 48: 511-7.
25. Llorente A, Perez-Valero I, Garcia E et al. Mortality risk factors in patients with zygomycosis: a retrospective and multicentre study of 25 cases. Enferm Infecc Microbiol Clin 2011; 29: 263-8.
26. Nisbet-Brown E, Olivieri NF, Giardina PJ et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597-602.
27. Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15: 1395-401.
28. Chakrabarti A, Chatterjee SS, Das A et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J 2009; 85: 573-81.
29. Chakrabarti A, Das A, Sharma A et al. Ten years' experience in zygomycosis at a tertiary care centre in India. J Infect 2001; 42: 261-6.
30. Ibrahim AS, Avanessian V, Spellberg B et al. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 2003; 47: 3343-4.
31. Singh N, Aguado JM, Bonatti H et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200: 1002-11.
32. Gleissner B, Schilling A, Anagnostopolous I et al. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004; 45: 1351-60.